AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo preclinical studies

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 509-517

  Webber, Stephanie ^a   Bartlett, Charlotte A ^a   Boritzki, Theodore J ^a   Hilliard, Jill A ^a   Howland, Eleanor F ^a   Johnston, Amanda L ^a   Kosa, Maha ^a   Margosiak, Stephen A ^a   Morse, Cathy A ^a   Shetty, Bhasker V ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

AG337; Antifolate; Thymidylate synthase

Indexed keywords

DEOXYRIBONUCLEOTIDE; FOLIC ACID ANTAGONIST; NEW DRUG; NOLATREXED; RECOMBINANT ENZYME; RIBONUCLEOTIDE; THYMIDINE TRIPHOSPHATE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; TRITIUM;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG ELIMINATION; ENZYME INHIBITION; ENZYME KINETICS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA L 1210; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; GROWTH INHIBITORS; HUMANS; LEUKEMIA L1210; LEUKEMIA L5178; MICE; QUINAZOLINES; RATS; SOLUBILITY; THYMIDYLATE SYNTHASE;

EID: 9044239673     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050422     Document Type: Article

References (28)

1. Appelt K, Bacquet RJ, Bartlett CA, Booth CLJ, Freer ST, Fuhry MM, Gehring MR, Herrmann SM, Howland EF, Janson CA, Jones TR, Kan C-C, Kathardekar V, Lewis KK, Marzoni GP, Matthews DA, Mohr C, Moomaw EW, Morse CA, Oatley SJ, Ogden RC, Reddy MR, Reich SH, Schoettlin WS, Smith WW, Varney MD, Villafranca JE, Ward RW, Webber S, Webber SE, Welsh KM, White J (1991) Design of enzyme inhibitors using iterative protein crystallographic analysis. J Med Chem 34: 1925
2. 10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4: 1245
3. Calvete JA, Balmanno K, Taylor GA, Rafi I, Newell DR, Lind MJ, Calvert AH (1994) Preclinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor, AG337. Proc Am Assoc Cancer Res 35: 306
4. 10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur J Cancer Clin Oncol 24: 733
5. Dev IK, Dallas WS, Ferone R, Hanlon M, McKee DD, Yates BB (1994) Mode of binding of folate analogs to thymidylate synthase. Evidence of two asymmetric but interactive substrate binding sites. J Biol Chem 269: 1873
6. Duch DS, Banks S, Dev IK, Dickenson SH, Ferone R, Heath LS, Humphries J, Knick V, Pendergast W, Singer S, Smith GK, Water K, Wilson HR (1993) Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53: 810
7. Ericksson S, Thelander L, Akerman M (1979) Allosteric regulation of calf thymus ribonucleoside diphosphate reductase. Biochemistry 18: 2948
8. Fry DW, Anderson LA, Borst M, Goldman ID (1983) Analysis of the role of membrane transport and polyglutamylation of methotrexate in the gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 43: 1087
9. Garrett C, Santi DV (1979) A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 99: 268
10. Greene JM, MacKenzie RE, Matthews RG (1988) Substrate flux through methylenetetrahydrofolate dehydrogenase. Predicted effects of the concentration of methylenetetrahydrofolate on its partitioning into pathways leading to nucleotide biosynthesis or methionine regeneration. Biochemistry 27: 8014
11. Jackman AL, Calvert AH, Hart LI, Harrap KR (1984) Inhibition of thymidylate synthetase by the new quinazoline antifolate CB3717; enzyme purification and kinetics. In: DeBruyn CHMM, Simmonds HA, Muller M (eds) Purine metabolism in man - IV, 165B. Plenum Publishing, New York, p 375
12. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (WIL2) systems in vitro and in L1210 in vivo. Cancer Res 50: 5212
13. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR (1991) ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 51: 5579
14. 10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol 42: 1885
15. 10-propargyl-5,8-dideazafolate as antitumor agents. Adv Exp Med Biol 338: 579
16. Jansen G, Westerhof GR, Schornagel JH, Jackman AL, Boyle FT (1993) The reduced folate/methotrexate carrier as a membrane-associated folate binding protein as transport routes for novel antifolates: structure-activity relationships. Adv Exp Med Biol 338: 767
17. 3H. J Biol Chem 242: 109
18. Lui MS, Jackson RC, Weber G (1979) Enzyme pattern-directed chemotherapy. Effects of antipyrimidine combinations on the ribonucleotide content of hepatomas. Biochem Pharmacol 28: 1189
19. Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors. Biochim Biophys Acta 185: 269
20. Mosmann TJ (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 5: 55
21. Rafi I, Taylor GA, Balmanno K, Calvete JA, Newell DR, Lind MJ, Calvert AH (1994) A phase I study of the novel antifolate 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (AG337) given by a 24 hour intravenous continuous infusion. Proc Am Assoc Cancer Res 35: 306
22. 10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem Pharmacol 37: 4047
23. Sirotnak FM, De Graw JI (1984) Selective antitumor action of folate analogs. In: Sirotnak FM, Burchall JJ, Ensminger WD, Montgomery JA (eds) Folate antagonists as therapeutic agents, vol 1. Academic Press, New York, p 43
24. Tattersall MHN, Harrap KR (1973) Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil. Cancer Res 33: 3086
25. Webber S, Shetty BV, Johnston A, Welsh K, Varney M, Deal J, Morse C, Soda K (1992) In vitro properties and antitumor activity of AG-331, a novel lipophilic thymidylate synthase inhibitor. Proc Am Assoc Cancer Res 33: 413
26. Webber SE, Bleckman TM, Attard J, Deal JG, Kathardekar V, Welsh KM, Webber S, Janson CA, Matthews DA, Smith WW, Freer ST, Jordan SR, Bacquet RJ, Howland EF, Booth CLJ, Ward RW, Herrmann SM, White J, Morse CA, Hilliard JA, Bartlett CA (1993) Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36: 733
27. Webber S, Johnston A, Shetty B, Webber SE, Welsh K, Hilliard J, Kosa M, Morse C, Soda K (1993) Preclinical studies on AG-337, a novel lipophilic thymidylate synthase inhibitor. Proc Am Assoc Cancer Res 34: 273
28. Yalowich JC, Kalman TI (1985) Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem Pharmacol 34: 2319